
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has demonstrated a robust financial outlook, highlighted by management's upward revision of FY 2025 non-GAAP EPS guidance to $12.09-$12.29, reflecting an increase of 10 cents from previous estimates. Additionally, the company has revised its revenue forecast for FY 2025 to approximately $59.7 billion, marking a $700 million increase, which underscores its strong market position. The recent acquisitions of Cerevel and ImmunoGen further enhance AbbVie's product portfolio, solidifying its growth potential in key therapeutic areas like neuroscience and oncology.
Bears say
AbbVie faces significant downside risks, particularly concerning disappointing commercial execution across key assets like Skyrizi, Rinvoq, and Botox, as well as potential setbacks in clinical data and regulatory approvals for both marketed products and pipeline assets. The company's aesthetics business, which contributed approximately 9.2% to overall sales in FY 2024, is especially vulnerable to macroeconomic challenges and consumer spending volatility. Additionally, despite a slight EPS beat in 1Q 2025, higher-than-expected selling, general, and administrative (SG&A) and research and development (R&D) expenses continued to weigh on overall financial performance, raising concerns about cost management and sustainability.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares